Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

pegfilgrastim 16Filgrastim 9Docetaxel 6Cyclophosphamide 6pegylated granulocyte colony-stimulating factor 3eflapegrastim 3liposomal amphotericin B 2Doxorubicin 2Moxibustion 1Methotrexate 1Maxy G34 1MYL-1401H 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Epirubicin 1EC regimen 1Cefepime 1Caspofungin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neutropenia × EC regimen × Breast × Clear all
NCT02527746 2024-02-23

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

EVIVE Biotechnology

Phase 1 Completed
18 enrolled 22 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡